 The shares of Aptevo Therapeutics Inc NASDAQ:APVO are soaring today, up 35 to trade at 8.75 at last check, after the biotech concern announced that one high-risk cancer patient had a complete remission after being treated with its experimental drug, APVO436, combined with chemotherapy. 